Contact
searchSearch
HMP Global
Research Highlights

Mirikizumab Improves Quality of Life and Work Productivity in Moderate to Severe Crohn’s Disease

Jessica Garlewicz
09/04/2025

Findings from the Phase 3 VIVID-1 study show that mirikizumab significantly improves health-related quality of life (HRQoL) and work productivity in patients with moderately to severely active Crohn’s disease (CD), with sustained benefits through 52 weeks of treatment.

A total of 579 patients received mirikizumab and 199 received placebo. HRQoL was assessed using multiple validated tools, including the Inflammatory Bowel Disease Questionnaire (IBDQ), SF-36, and EQ-5D-5L visual analog scale, while work productivity was evaluated using the Work Productivity and Activity Impairment: CD (WPAI:CD) measure.

At weeks 12 and 52, mirikizumab-treated patients showed significantly greater improvements in IBDQ total and domain scores, SF-36 component scores, and EQ-5D-5L scores compared to placebo (all P < 0.001). These improvements were mirrored by enhanced work-related outcomes.

At week 12, mirikizumab significantly reduced absenteeism (P = 0.001), presenteeism (P = 0.005), activity impairment (P < 0.001), and overall work impairment (P = 0.002) compared to placebo.

“Patients with moderately to severely active CD treated with mirikizumab reported clinically meaningful improvements in HRQoL and work productivity vs placebo at week 12, which were maintained at week 52,” the study authors concluded.

The authors also reported that a greater proportion of patients receiving mirikizumab achieved IBDQ response, IBDQ remission, and clinically important improvements in both the physical and mental component summaries of the SF-36 (all P < 0.001).

The findings highlight mirikizumab as a therapeutic option that delivers not only symptom relief but also sustained improvements in quality of life and functional outcomes for patients with moderate to severe CD.

 

Reference

Lee SD, Vermeire S, Ungaro R, et al. Mirikizumab improves quality of life and work productivity in patients with moderately to severely active Crohn's disease: results from the phase 3 VIVID-1 study. Am J Gastroenterol. Published March 13, 2025. doi:10.14309/ajg.0000000000003410

 

© 2025 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of the Advances in Inflammatory Bowel Disease Network or HMP Global, their employees, and affiliates. 

Latest News

Research Highlights
Concomitant Medications Do Not Alter Efficacy of Advanced Therapies in Ulcerative Colitis, Study Finds
09/18/2025
Jessica Garlewicz
New study findings suggest that most baseline concomitant therapies do not require modification or exclusion when initiating advanced therapy in clinical trial settings.
New study findings suggest that most baseline concomitant therapies do not require modification or exclusion when initiating advanced therapy in clinical trial settings.
New study findings suggest that...
09/18/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Persistent Prothrombotic State Observed in Patients With ASUC
09/04/2025
Rebecca Mashaw
New findings show patients with acute severe ulcerative colitis remain at elevated thrombotic risk for up to 12 weeks post-hospitalization.
New findings show patients with acute severe ulcerative colitis remain at elevated thrombotic risk for up to 12 weeks post-hospitalization.
New findings show patients with...
09/04/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Upadacitinib Improves Outcomes in Fistulizing Crohn’s Disease
09/04/2025
Rebecca Mashaw
Patients with fistulizing Crohn’s disease achieved higher rates of fistula resolution and clinical response with upadacitinib versus placebo.
Patients with fistulizing Crohn’s disease achieved higher rates of fistula resolution and clinical response with upadacitinib versus placebo.
Patients with fistulizing...
09/04/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Pelvic MRI Detects Subclinical Perianal Disease in Pediatric Crohn’s Disease
09/04/2025
Jessica Garlewicz
The study highlights a diagnostic blind spot in pediatric CD management and supports adding baseline pelvic MRI to initial workup, even in the absence of perianal symptoms.
The study highlights a diagnostic blind spot in pediatric CD management and supports adding baseline pelvic MRI to initial workup, even in the absence of perianal symptoms.
The study highlights a...
09/04/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Mirikizumab Improves Quality of Life and Work Productivity in Moderate to Severe Crohn’s Disease
09/04/2025
Jessica Garlewicz
Study findings highlight mirikizumab as a therapeutic option that delivers not only symptom relief but also sustained improvements in quality of life and functional outcomes for patients with moderate to severe CD.
Study findings highlight mirikizumab as a therapeutic option that delivers not only symptom relief but also sustained improvements in quality of life and functional outcomes for patients with moderate to severe CD.
Study findings highlight...
09/04/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Risankizumab Improves Symptom Resolution and Quality of Life in Ulcerative Colitis
09/04/2025
Jessica Garlewicz
Risankizumab led to earlier and sustained improvements in individual symptoms—including abdominal pain, bowel urgency, fecal incontinence, and sleep interruption
Risankizumab led to earlier and sustained improvements in individual symptoms—including abdominal pain, bowel urgency, fecal incontinence, and sleep interruption
Risankizumab led to earlier and...
09/04/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Guselkumab Demonstrates Efficacy and Safety in Moderate-to-Severe Crohn’s Disease
09/04/2025
Jessica Garlewicz
The study met all primary and multiplicity-controlled secondary endpoints, including clinical and endoscopic outcomes through 48 weeks.
The study met all primary and multiplicity-controlled secondary endpoints, including clinical and endoscopic outcomes through 48 weeks.
The study met all primary and...
09/04/2025
Advances in Inflammatory Bowel Disease Network
News
Validation of a Simple Ultrasound Score for Crohn’s Disease
08/28/2025
Rebecca Mashaw
A multicenter study confirms the accuracy and reliability of a simplified ultrasound score for assessing Crohn’s disease activity.
A multicenter study confirms the accuracy and reliability of a simplified ultrasound score for assessing Crohn’s disease activity.
A multicenter study confirms the...
08/28/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Real-World Effectiveness and Safety of Risankizumab in Crohn’s Disease
08/21/2025
Rebecca Mashaw
Risankizumab demonstrates sustained clinical benefit and favorable safety in Crohn’s disease, including among ustekinumab-experienced patients.
Risankizumab demonstrates sustained clinical benefit and favorable safety in Crohn’s disease, including among ustekinumab-experienced patients.
Risankizumab demonstrates...
08/21/2025
Advances in Inflammatory Bowel Disease Network
Research Highlights
Intestinal Ultrasound Activity in Pregnancy Predicts Adverse Outcomes in Women With Inflammatory Bowel Disease
08/21/2025
Rebecca Mashaw
Intestinal ultrasound during pregnancy may more reliably predict adverse maternal and neonatal outcomes from inflammatory bowel disease than clinical or biochemical assessments alone, recent research revealed.
Intestinal ultrasound during pregnancy may more reliably predict adverse maternal and neonatal outcomes from inflammatory bowel disease than clinical or biochemical assessments alone, recent research revealed.
Intestinal ultrasound during...
08/21/2025
Advances in Inflammatory Bowel Disease Network

Latest Podcasts

IBD Drive time logo
Podcast
IBD Drive Time: Jason Schairer, MD, on Extraintestinal Manifestations in IBD
09/25/2025
Jason Schairer, MD; Raymond Cross, MD
Host Raymond Cross, MD, and guest Dr Jason Schairer discuss the varieties of extraintestinal manifestations that may be seen in patients with IBD, how to diagnose them and when to rely on colleagues in dermatology, ophthalmology, and...
Host Raymond Cross, MD, and guest Dr Jason Schairer discuss the varieties of extraintestinal manifestations that may be seen in patients with IBD, how to diagnose them and when to rely on colleagues in dermatology, ophthalmology, and...
Host Raymond Cross, MD, and...
09/25/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
Ryan Ungaro, MD, on Perturbances in Metabolic Pathways in IBD
09/02/2025
Raymond Cross, MD; Ryan Ungaro
Dr Raymond Cross discusses with Dr Ryan Ungaro how the Mount Sinai Crohn's and Colitis Registry, a prospective observational cohort, is being studied to determine if its detailed clinical information and omics data collected can identify new...
Dr Raymond Cross discusses with Dr Ryan Ungaro how the Mount Sinai Crohn's and Colitis Registry, a prospective observational cohort, is being studied to determine if its detailed clinical information and omics data collected can identify new...
Dr Raymond Cross discusses with...
09/02/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
Anita Afzali, MD, on the ACG Guidelines for Crohn's Disease
08/18/2025
Raymond Cross, MD; Anita Afzali
Dr Anita Afzali reviews with Dr Raymond Cross the updated guidelines for managing Crohn's disease from the American College of Gastroenterology,
Dr Anita Afzali reviews with Dr Raymond Cross the updated guidelines for managing Crohn's disease from the American College of Gastroenterology,
Dr Anita Afzali reviews with Dr...
08/18/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: David Rubin, MD, on the ACG Guidelines for Ulcerative Colitis
08/04/2025
David T. Rubin, MD; Raymond Cross, MD
Host Raymond Cross, MD, discusses the updates in the American College of Gastroenterology guideline on managing ulcerative colitis with first author David Rubin, MD.
Host Raymond Cross, MD, discusses the updates in the American College of Gastroenterology guideline on managing ulcerative colitis with first author David Rubin, MD.
Host Raymond Cross, MD,...
08/04/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: Corey Siegel, MD, on Defining Quality Care for IBD
07/15/2025
Raymond Cross, MD; Corey A. Siegel, MD, MS
Host Raymond Cross, MD, and Dr Corey Siegel delve into the factors that constitute quality care for patients with IBD today, and how the definition of quality care has evolved over time.
Host Raymond Cross, MD, and Dr Corey Siegel delve into the factors that constitute quality care for patients with IBD today, and how the definition of quality care has evolved over time.
Host Raymond Cross, MD, and Dr...
07/15/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: Dr Susan Kais on Pregnancy and IBD
06/19/2025
Raymond Cross, MD
Drs Raymond Cross and Susan Kais delve into the issues surrounding fertility, pregnancy, postpartum care and more for women with IBD.
Drs Raymond Cross and Susan Kais delve into the issues surrounding fertility, pregnancy, postpartum care and more for women with IBD.
Drs Raymond Cross and Susan Kais...
06/19/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
Drs Sara Horst and Jordan Axelrad Review Studies on Infection, Malignancy With IBD Therapies
06/06/2025
Sara Horst, MD; Jordan Axelrad
Guest host Sara Horst, MD, talks with Dr Jordan Axelrad about two studies on safety of advanced therapies for inflammatory bowel disease, including risks of infection and malignancy.
Guest host Sara Horst, MD, talks with Dr Jordan Axelrad about two studies on safety of advanced therapies for inflammatory bowel disease, including risks of infection and malignancy.
Guest host Sara Horst, MD, talks...
06/06/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: Miguel Regueiro, MD, on Providing Multidisciplinary Care in IBD
05/21/2025
Miguel D. Regueiro, MD; Raymond Cross, MD
Dr Regueiro and IBD Drive Time host Raymond Cross, MD, discuss the importance and the challenges of providing multidisciplinary care to patients with IBD, including dietary guidance, mental health services, and more.
Dr Regueiro and IBD Drive Time host Raymond Cross, MD, discuss the importance and the challenges of providing multidisciplinary care to patients with IBD, including dietary guidance, mental health services, and more.
Dr Regueiro and IBD Drive Time...
05/21/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
Edward Barnes, MD, on Antibiotics and Risk of Pouchitis
05/20/2025
Edward L. Barnes; Sara Horst, MD
Guest host Sara Horst, MD, talks with Dr Ed Barnes about his research into whether antibiotics taken a year before an IPAA may contribute to the development of pouchitis.
Guest host Sara Horst, MD, talks with Dr Ed Barnes about his research into whether antibiotics taken a year before an IPAA may contribute to the development of pouchitis.
Guest host Sara Horst, MD, talks...
05/20/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: Edward Barnes, MD, on Pouch Complications
05/09/2025
Guest host Sara Horst, MD, and Dr Edward Barnes discuss complications of ileal pouch-anal anastamosis surgery and whether recent use of antibiotics puts patients at risk of pouchitis.
Guest host Sara Horst, MD, and Dr Edward Barnes discuss complications of ileal pouch-anal anastamosis surgery and whether recent use of antibiotics puts patients at risk of pouchitis.
Guest host Sara Horst, MD, and...
05/09/2025
Advances in Inflammatory Bowel Disease Network

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use